JP2009530359A5 - - Google Patents

Download PDF

Info

Publication number
JP2009530359A5
JP2009530359A5 JP2009500919A JP2009500919A JP2009530359A5 JP 2009530359 A5 JP2009530359 A5 JP 2009530359A5 JP 2009500919 A JP2009500919 A JP 2009500919A JP 2009500919 A JP2009500919 A JP 2009500919A JP 2009530359 A5 JP2009530359 A5 JP 2009530359A5
Authority
JP
Japan
Prior art keywords
tumor
use according
establishment
growth
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009500919A
Other languages
Japanese (ja)
Other versions
JP2009530359A (en
Filing date
Publication date
Priority claimed from GBGB0605685.7A external-priority patent/GB0605685D0/en
Application filed filed Critical
Publication of JP2009530359A publication Critical patent/JP2009530359A/en
Publication of JP2009530359A5 publication Critical patent/JP2009530359A5/ja
Pending legal-status Critical Current

Links

Claims (18)

対象の腫瘍の成長または成立（establishment）に対する適応免疫を誘導する医薬の製造における、溶解性化合物の使用。   Use of a soluble compound in the manufacture of a medicament that induces adaptive immunity to the growth or establishment of a subject's tumor. 対象の腫瘍の成立（establishment）、成長または増殖に対するワクチンとして使用する医薬の製造における、溶解性化合物の使用。   Use of a soluble compound in the manufacture of a medicament for use as a vaccine against the establishment, growth or proliferation of a subject's tumor. 前記溶解性化合物が、第１の腫瘍の細胞溶解を介して、第２の腫瘍の成立（establishment）、成長または成立（establishment）を阻害する免疫応答を生じさせる、請求項１または２に記載の使用。   3. The lytic compound of claim 1 or 2, wherein the lytic compound produces an immune response that inhibits the establishment, growth or establishment of a second tumor via cell lysis of the first tumor. use. 前記溶解性化合物がペプチドである、請求項１から３のいずれか一項に記載の使用。   4. Use according to any one of claims 1 to 3, wherein the soluble compound is a peptide. 前記ペプチドが、最少で３個のアミノ酸の長さであり、１以上の正電荷を有する、請求項４に記載の使用。   Use according to claim 4, wherein the peptide is a minimum of 3 amino acids in length and has one or more positive charges. 前記ペプチドが、かさ高く親油性である基を含む、請求項４または５に記載の使用。   6. Use according to claim 4 or 5, wherein the peptide comprises a bulky and lipophilic group. 前記かさ高く親油性である基が７個以上の非水素原子を有する、請求項６に記載の使用。   7. Use according to claim 6, wherein the bulky and lipophilic group has 7 or more non-hydrogen atoms. 前記溶解性ペプチドが、少なくとも１個のビフェニルアラミン（Ｂｉｐ）および／または少なくとも１個のジフェニルアラミン（Ｄｉｐ）残基および／または１〜５個のトリプトファン残基を含む、請求項７に記載の使用。   8. The soluble peptide according to claim 7, comprising at least one biphenylalamine (Bip) and / or at least one diphenylalamine (Dip) residue and / or 1 to 5 tryptophan residues. Use of. 前記溶解性化合物がペプチド類似物である、請求項１から３のいずれか一項に記載の使用。   4. Use according to any one of claims 1 to 3, wherein the soluble compound is a peptide analogue. 前記溶解性化合物が腫瘍内に送達される、請求項１から９のいずれか一項に記載の使用。   10. Use according to any one of claims 1 to 9, wherein the soluble compound is delivered into the tumor. 前記成長の阻害が前記腫瘍の退縮である、請求項１から１０のいずれか一項に記載の使用。   11. Use according to any one of claims 1 to 10, wherein the growth inhibition is regression of the tumor. 前記成長の阻害が第２の腫瘍の成立（establishment）防止を含む、請求項１から１１のいずれか一項に記載の使用。   12. Use according to any one of the preceding claims, wherein the inhibition of growth comprises prevention of establishment of a second tumor. 前記第２の腫瘍が二次性腫瘍である、請求項１から１２のいずれか一項に記載の使用。   13. Use according to any one of claims 1 to 12, wherein the second tumor is a secondary tumor. 前記第１の腫瘍および前記第２の腫瘍が類似の免疫特性を有する、請求項１から１３のいずれか一項に記載の使用。   14. Use according to any one of claims 1 to 13, wherein the first tumor and the second tumor have similar immune properties. 前記第１の腫瘍および前記第２の腫瘍が同一の癌タイプである、請求項１４に記載の使用。   15. Use according to claim 14, wherein the first tumor and the second tumor are of the same cancer type. 前記腫瘍がリンパ腫、癌腫および肉腫からなる群から選択される、請求項１から１５のいずれか一項に記載の使用。   16. Use according to any one of claims 1 to 15, wherein the tumor is selected from the group consisting of lymphoma, carcinoma and sarcoma. 前記腫瘍が良性腫瘍である、請求項１から１５のいずれか一項に記載の使用。   16. Use according to any one of claims 1 to 15, wherein the tumor is a benign tumor. 前記対象がヒトである、請求項１〜１７のいずれかに記載の使用。 18. Use according to any of claims 1 to 17 , wherein the subject is a human.
JP2009500919A 2006-03-21 2007-03-21 Tumor growth inhibition Pending JP2009530359A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0605685.7A GB0605685D0 (en) 2006-03-21 2006-03-21 Inhibition of tumour growth
PCT/GB2007/000993 WO2007107748A2 (en) 2006-03-21 2007-03-21 Inhibition of tumour growth

Publications (2)

Publication Number Publication Date
JP2009530359A JP2009530359A (en) 2009-08-27
JP2009530359A5 true JP2009530359A5 (en) 2010-05-06

Family

ID=36383910

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009500919A Pending JP2009530359A (en) 2006-03-21 2007-03-21 Tumor growth inhibition

Country Status (8)

Country Link
EP (1) EP2010204A2 (en)
JP (1) JP2009530359A (en)
CN (1) CN101466391A (en)
AU (1) AU2007228574B2 (en)
CA (1) CA2646589C (en)
GB (1) GB0605685D0 (en)
NO (1) NO20084053L (en)
WO (1) WO2007107748A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821616D0 (en) * 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
GB201401877D0 (en) * 2014-02-04 2014-03-19 Univ Tromsoe Peptides
JP6813258B2 (en) * 2014-12-11 2021-01-13 リティックス バイオファーマ エイエス Chemotherapy combination
JP6767096B2 (en) * 2014-12-11 2020-10-14 リティックス バイオファーマ エイエス Combination of immune checkpoint inhibitors
US11491139B2 (en) * 2015-02-12 2022-11-08 The Johns Hopkins University Inhibition of YAP for breaking tumor immune tolerance
GB201601868D0 (en) 2016-02-02 2016-03-16 Lytix Biopharma As Methods
WO2024133580A1 (en) 2022-12-20 2024-06-27 Lytix Biopharma As Medical products containing an aqueous formulation of a peptide
WO2024133588A1 (en) 2022-12-20 2024-06-27 Lytix Biopharma As Compositions comprising an oncolytic peptide and chitosan

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861478A (en) * 1987-07-06 1999-01-19 Helix Biomedix, Inc. Lytic peptides
KR970006154B1 (en) * 1987-07-06 1997-04-24 루이지아나 스테이트 유니버시티 아그리컬춰럴 앤드 메카니칼 컬리지 Inhibition of eucaryotic pathogens and neoplasms and stimulation of fibroblasts and lymphocytes with lytic peptides
US5773413A (en) * 1993-06-04 1998-06-30 Demeter Biotechnologies, Ltd. Method of combating mammalian neoplasias, and lytic peptides therefor
IL113244A0 (en) * 1994-04-08 1995-07-31 Demeter Biotech Ltd Method of combating mammalian neoplasia and lytic peptides therefor
GB9818938D0 (en) * 1998-08-28 1998-10-21 Alpharma As Bioactive peptides

Similar Documents

Publication Publication Date Title
JP2009530359A5 (en)
SA519402405B1 (en) Human immunodeficiency virus inhibitor compounds
JP2017057230A5 (en)
JP2012500001A5 (en)
JP2016536312A5 (en)
WO2020056198A3 (en) Substituted benzazepine compounds, conjugates, and uses thereof
JP2015522573A5 (en)
MX2018005204A (en) Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2.
SI1802650T1 (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
EP4241850A3 (en) Mdm2 inhibitors and combinations thereof
NZ585226A (en) Inhibitors of human immunodeficiency virus replication
TNSN06071A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
AU2003296993A8 (en) Cyclopropyl compounds as ccr5 antagonists
AU4563101A (en) Biodegradable immunomodulatory formulations and methods for use thereof
TW200833684A (en) 5,6-ring annulated indole derivatives and methods of use thereof
UA92000C2 (en) 1-benzylindole-2-carboxamide derivatives
CL2004000270A1 (en) COMPOUNDS DERIVED FROM PIRAZOL, ITS ADDITION SALTS ACIDS, HIV DISORDERS AND GENETICALLY RELATED VIRUSES. HYDRATES, SOLVATES; PHARMACEUTICAL COMPOSITIONS; AND ITS USE IN THE TREATMENT OF GENETICALLY RELATED HIV DISORDERS AND VIRUSES.
JP2016502515A5 (en)
JP2014050390A5 (en)
WO2009038026A1 (en) Ctl inducer composition
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
JP2015502926A5 (en)
WO2016086153A3 (en) Use of hsp90 inhibitors for the treatment of hiv infections and aids
EP2555798A4 (en) Methods and compositions for inhibiting hiv transmission
JP2008523067A5 (en)